The case of "Missing Causal Genes" and the practice of medicine

Circulation Research

Volumn 119, Issue 1, 2016, Pages 21-24

  Marian, Ali J ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

genetic testing; hypertrophic; introns; meiosis; mutation; variant

Indexed keywords

CONNECTIN;

DNA REPLICATION; DNA SEQUENCE; ENVIRONMENTAL FACTOR; EXON; FRAMESHIFT MUTATION; GENETIC BACKGROUND; GENETIC CONSERVATION; GENETIC DISORDER; GENETIC LINKAGE; GENETIC SCREENING; GENETIC VARIABILITY; GENETIC VARIATION; HEART ARRHYTHMIA; HUMAN; HUMAN GENOME; HYPERTROPHIC CARDIOMYOPATHY; INDEL MUTATION; INTRON; MEDICAL ASSESSMENT; MEDICAL GENETICS; MEDICAL PRACTICE; MEIOSIS; MISSENSE MUTATION; PRIORITY JOURNAL; PROGERIA; REVIEW; SEQUENCE ANALYSIS; STOP CODON; WHOLE EXOME SEQUENCING; ANIMAL; CARDIOVASCULAR DISEASE; GENETIC PREDISPOSITION; GENETICS; PROCEDURES; TRENDS; WHOLE GENOME SEQUENCING;

ANIMALS; CARDIOVASCULAR DISEASES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; WHOLE GENOME SEQUENCING;

EID: 84975894206     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.308830     Document Type: Review

References (22)

1. Elliott PM, Anastasakis A, Borger MA, Authors/Task Force Members 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014 35 2733 2779. doi: 10.1093/eurheartj/ehu284
2. Ackerman MJ, Priori SG, Willems S, HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011 8 1308 1339. doi: 10.1016/j.hrthm.2011.05.020
3. Bezzina CR, Lahrouchi N, Priori SG, Genetics of sudden cardiac death. Circ Res 2015 116 1919 1936. doi: 10.1161/CIRCRESAHA.116.304030
4. Korf BR, Berry AB, Limson M, Marian AJ, Murray MF, O'Rourke PP, Passamani ER, Relling MV, Tooker J, Tsongalis GJ, Rodriguez LL, Framework for development of physician competencies in genomic medicine: report of the Competencies Working Group of the Inter-Society Coordinating Committee for Physician Education in Genomics. Genet Med 2014 16 804 809. doi: 10.1038/gim.2014.35
5. Campbell CD, Chong JX, Malig M, Ko A, Dumont BL, Han L, Vives L, O'Roak BJ, Sudmant PH, Shendure J, Abney M, Ober C, Eichler EE, Estimating the human mutation rate using autozygosity in a founder population. Nat Genet 2012 44 1277 1281. doi: 10.1038/ng.2418
6. Kong A, Frigge ML, Masson G, Rate of De novo mutations and the importance of father's age to disease risk. Nature 2012 488 471 475. doi: 10.1038/nature11396
7. Ho CY, Charron P, Richard P, Girolami F, Van Spaendonck-Zwarts KY, Pinto Y, Genetic advances in sarcomeric cardiomyopathies: state of the art. Cardiovasc Res 2015 105 397 408. doi: 10.1093/cvr/cvv025
8. Levy S, Sutton G, Ng PC, The diploid genome sequence of an individual human. PLoS Biol 2007 5 e254. doi: 10.1371/journal.pbio.0050254
9. Wheeler DA, Srinivasan M, Egholm M, The complete genome of an individual by massively parallel DNA sequencing. Nature 2008 452 872 876. doi: 10.1038/nature06884
10. De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, Lyonnet S, Stewart CL, Munnich A, Le Merrer M, Lévy N, Lamin a truncation in Hutchinson-Gilford progeria. Science 2003 300 2055. doi: 10.1126/science.1084125
11. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE, Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995 92 785 789. doi: 10.1161/01.CIR.92.4.785
12. Herman DS, Lam L, Taylor MR, Truncations of titin causing dilated cardiomyopathy. N Engl J Med 2012 366 619 628. doi: 10.1056/NEJMoa1110186
13. Golbus JR, Puckelwartz MJ, Fahrenbach JP, Dellefave-Castillo LM, Wolfgeher D, McNally EM, Population-based variation in cardiomyopathy genes. Circ Cardiovasc Genet 2012 5 391 399. doi: 10.1161/CIRCGENETICS.112.962928
14. Norton N, Li D, Rampersaud E, Morales A, Martin ER, Zuchner S, Guo S, Gonzalez M, Hedges DJ, Robertson PD, Krumm N, Nickerson DA, Hershberger RE, National Heart, Lung, and Blood Institute GO Exome Sequencing Project and the Exome Sequencing Project Family Studies Project Team Exome sequencing and genome-wide linkage analysis in 17 families illustrate the complex contribution of TTN truncating variants to dilated cardiomyopathy. Circ Cardiovasc Genet 2013 6 144 153. doi: 10.1161/CIRCGENETICS.111.000062
15. Marian AJ, Nature's genetic gradients and the clinical phenotype. Circ Cardiovasc Genet 2009 2 537 539. doi: 10.1161/CIRCGENETICS.109.921940
16. Marian AJ, Belmont J, Strategic approaches to unraveling genetic causes of cardiovascular diseases. Circ Res 2011 108 1252 1269. doi: 10.1161/CIRCRESAHA.110.236067
17. MacArthur DG, Manolio TA, Dimmock DP, Guidelines for investigating causality of sequence variants in human disease. Nature 2014 508 469 476. doi: 10.1038/nature13127
18. Marian AJ, Causality in genetics: the gradient of genetic effects and back to Koch's postulates of causality. Circ Res 2014 114 e18 e21. doi: 10.1161/CIRCRESAHA.114.302904
19. Abifadel M, Varret M, Rabès JP, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003 34 154 156. doi: 10.1038/ng1161
20. Seidah NG, Awan Z, Chrétien M, Mbikay M, PCSK9: A key modulator of cardiovascular health. Circ Res 2014 114 1022 1036. doi: 10.1161/CIRCRESAHA.114.301621
21. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015 372 1500 1509. doi: 10.1056/NEJMoa1500858
22. Robinson JG, Farnier M, Krempf M, ODYSSEY LONG TERM Investigators Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015 372 1489 1499. doi: 10.1056/NEJMoa1501031